Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) fell 4.4% during mid-day trading on Tuesday . The stock traded as low as $2.82 and last traded at $2.84, with a volume of 575,883 shares. The stock had previously closed at $2.97.

Separately, Maxim Group restated a “buy” rating on shares of Adamis Pharmaceuticals Corp. in a report on Tuesday, May 10th.

The firm’s 50 day moving average price is $2.86 and its 200 day moving average price is $5.24. The stock’s market capitalization is $60.15 million.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.